Why This Company May Win the Coronavirus Vaccine Race
Clinical-stage biotech companies like Moderna (NASDAQ: MRNA) and Inovio Pharmaceuticals (NASDAQ: INO) have been stealing the limelight in the coronavirus vaccine race. That may be due to their rapid entry into clinical trials and dramatic share-price gains. For example, Moderna's investigational coronavirus vaccine was the first to enter human trials, and Inovio was close behind. Moderna's shares have gained 258% this year, while Inovio has climbed 256%.
But these companies may not be closest to a win in this race. In fact, a big pharma rival might be on the brink of leaping across the finish line. I'm talking about Pfizer (NYSE: PFE), which partnered with Germany's BioNTech (NASDAQ: BNTX) in March. Why do I think Pfizer has a solid chance of winning the race? Let's take a closer look.
Image source: Getty Images.
Source Fool.com
